Crucell and DSM Biologics Announce PER.C6 Licensing Agreement with UMN Pharma
In addition, Crucell and DSM Biologics will provide UMN Pharma with various services including vector construction, clone generation, process development and cGMP manufacturing, through its own facilities in Groningen, The Netherlands and within the PER.C6® vendor network.
Under the terms of the agreement, UMN Pharma will pay a signing fee and annual maintenance fees. The additional services will also attract fees. Further financial details are not disclosed.
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.